GovChime
Notice ID: 4a0c245dd0f2446d924c030081e3674dAward NoticeAwarded

B--Transcription Factor Profiling for Chemical Mixtur

Awarded on September 23, 2021. Full description on SAM.gov.

Awarded tounder 68HE0B21P0625 (source: SAM.gov award notice)• $250.0K

Overview

Posted
September 23, 2021
Notice type
Award Notice
NAICS
541714: Research and Development in Biotechnology (except Nanobiotechnology)
Agency
Environmental Protection Agency

Notice details

Last updated
Sep 9, 2025
Award date
Sep 23, 2021
Award amount (SAM.gov award notice)
$250.0K

Identifiers

Solicitation number
68HE0B21Q0175
Notice ID
4a0c245dd0f2446d924c030081e3674d
Award number (PIID)
68HE0B21P0625

Description

Transcription Factor Profiling for Chemical Mixtures

Full description on SAM.gov

Award Overview

Award Number

68HE0B21P0625

Award Amount (SAM.gov award notice)

$250.0K

Award Date

Sep 23, 2021

Awardee

Awardee UEI

Z8AYGD59N8U4

Original Solicitation

Notice ID: 4a0c245dd0f2446d924c030081e3674d

Posted Date: Sep 23, 2021

Original Response Deadline: Not specified

Contacts

Documents

No documents available.

Lifecycle

Solicitation:68HE0B21Q0175
  1. Solicitation
  2. Awarded

This opportunity has been awarded.

  1. 3×
    SolicitationSep 6, 2021

    Transcription Factor Profiling for Chemical Mixtur

    Notice 153d5361aac94f92bbb8c2d022bd0c73 on SAM.gov

  2. AwardedCurrentSep 23, 2021

    B--Transcription Factor Profiling for Chemical Mixtur

    Notice 4a0c245dd0f2446d924c030081e3674d on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Please see attached Sources Sought. Questions & Answers attached.
48%
Market Research11/12/2026
Washington Headquarters Services (WHS) Acquisition Directorate (AD) is releasing this solicitation electronically only, via a request for proposal (RFP) on Procurement Integrated Enterprise Environment (PIEE) Solicitation Module (https://piee.eb.mil/) with a notice and link transmitted to www.sam.gov for Publications Oral History and Research Assistant Support Services. This electronic version of the Request for Proposal (RFP) is the official version for this acquisition. No hard copy of this solicitation will be issued. Offerors will be notified of any and all applicable amendments to this solicitation electronically via PIEE. Offerors shall submit their proposals electronically via PIEE Solicitation Module. Any proposal received outside of the PIEE Solicitation Module will not be considered and will not be evaluated. Any proposal received after the due date and time specified for receipt will be considered late and will be rejected. The Government anticipates award of single award contract to the responsible Offeror that submits the offer that is most advantageous to the Government based upon the evaluation factors discussed in this RFP. This solicitation is a 100% set aside for small business concerns under NAICS code 541720 Research and Development in the Social Sciences and Humanities. The Government intends to award without discussions but reserves the right to conduct discussions if determined to be in the Governments best interest.
46%
Solicitation08/21/2026
Pre-Solicitation Notice of Intent to Sole Source Contracting Activity: U.S. Environmental Protection Agency (EPA), Office of the Chief Procurement Officer (OCPO), Water, Tribal, and Science Division (WTSD) Description of Services: The EPA requires histology and pathology services of maternal and neonatal rodent specimen organs at the US EPA Headquarters, 1200 Pennsylvania Ave, Washington, DC 20460. Experimental Pathology Laboratories, Inc. (EPL) experience in the toxicologic pathology of environmental contaminants — including PFAS, phthalates, air pollutants, and endocrine-disrupting compounds — is highly relevant to the scope of this acquisition. EPA and other federal research offices have a long history of contracting histopathology services with EPL. Consequently, EPL has extensive experience meeting EPA’s Quality Assurance (QA) Program requirements. Its laboratories comply with Good Laboratory Practice (GLP) regulations and have passed GLP inspections by the FDA and EPA in the past decade. Importantly, the work proposed under this acquisition continues several larger studies previously processed and evaluated. Deviations from established protocols are unacceptable within the same or related studies, as they introduce unknown errors and compromise data integrity. Finally, EPL is a local vendor, allowing the program office to hand-deliver delicate samples in fixative (no shipping). This acquisition is anticipated to be a firm-fixed purchase order. The North American Industry Classification System (NAICS) code is 541714 – Research and Development in Biotechnology (except Nanobiotechnology). The product and service code (PSC) is AZ11 – R&D-Other Research and Development. Acquisition Procedures: The EPA intends to award a sole source purchase order to EPL in accordance with RFO FAR 6.103-1(b) and simplified acquisition procedures in accordance with FAR part 12. The sole source justification will be made publicly available in accordance with RFO FAR 6.301. EPL is the only known source able to satisfy this requirement. Notwithstanding, in accordance with RFO FAR 5.101(c)(4)(vi), responsible sources may elect to submit a capability statement, proposal, or quotation. A determination not to compete the proposed firm-fixed-price contract based upon the responses received to this notice is solely within the discretion of the Government. Responses to this notice must be submitted to the contracting officer, Paige Long, at long.paige@epa.gov no later than November 30, 2026. Telephone responses will not be honored. Estimated award date is December 3, 2026. FedConnect is a web portal that connects agencies and vendors to streamline the process of doing business with the federal government. Through FedConnect contractors will be able to receive, review and respond to contract pre- and post-award actions and documents such as correspondence, request for proposals, tasking instruments and contract modifications. The use of FedConnect also furthers the EPAs commitment to moving towards a paperless acquisition environment by reducing its carbon footprint and conducting its business in an ecologically friendly manner. There is no charge to use FedConnect. Vendors can register with FedConnect at www.fedconnect.net/FedConnect/. For assistance in registering or for other FedConnect technical questions please call the FedConnect Help Desk at (800) 899-6665 or email fcsupport@unisonglobal.com In addition, all vendors must be registered in the System for Award Management (SAM), as this facilitates registration for FedConnect. Please note that vendors MUST have their SAM profile set to public, otherwise FedConnect will not be able to access the SAM information required to validate vendor credentials. Registration may be completed and information regarding the registration process may be obtained at http://www.sam.gov. There is no charge for registration in SAM.
41%
Special Notice11/30/2026
This is a continuous, open announcement with no deadline unless specifically noted. (Please note this posting was formerly the Threat Agnostic Host-Directed Therapeutics/HEALER PBA. If a white paper was previously submitted under the HEALER name, then the submission is still valid for the revised annoucement.) Issuing Organization Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) 1. Strategic Opportunity The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) invites interested parties to enter into the CBRN Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. To maximize the efficacy of the advanced MCMs detailed in this agreement, the CPE CBRND recognizes that therapeutic intervention is intrinsically linked to rapid, and effective patient diagnosis. Consequently, this PBA includes an integrated focus on diagnostics. This PBA establishes a unified, open, and continuous network of pre-qualified partners to accelerate the development, testing, and fielding of next-generation CBRN medical defense solutions. The goal is to create a streamlined framework for awarding follow-on project agreements, fostering a long-term, collaborative relationship with the Government. 2. Program Vision: Building Holistic Threat Resilience The overarching goal of the CBRN MCM PBA is to develop and field a comprehensive suite of MCMs, inclusive of medical devices, drugs and biologics, to protect the warfighter within a complex and evolving CBRN threat space. This PBA is designed as an agile agreement supporting a wide range of acquisition strategies and technologies, from rapid prototyping to late-stage development and FDA licensure or clearance. To build an integrated layered defense, the Government seeks innovative solutions across the continuum of care. This includes both pathogen or agent-based and host-based diagnostics, treatments, pre-exposure or post-exposure prophylactic countermeasures, as well as ruggedized formulations, novel drug delivery systems, and adaptable platform technologies capable of rapidly pivoting to address new and emerging threats. This integrated approach will ensure the development of a diverse and robust portfolio of MCM capabilities, preserving the Joint Force through enhanced resilience. Examples of capabilities sought under this PBA include, but are not limited to: Host-Targeted Resilience: Development efforts focus on providing layered physiological protection and treatment by targeting critical host systems. The Government welcomes innovative, threat-agnostic MCM candidates that enhance host resilience, including investigational drugs with multi-indication potential in civilian critical care, establishing a sustainable, long-term therapeutic pipeline. To meet the demands of far-forward operations, priority is placed on drug candidates designed for rapid employment in austere environments. This includes formulations featuring simplified routes of administration (such as oral, intranasal, or autoinjector delivery) that can be administered without specialized medical infrastructure. Examples of sought-after mechanisms of action include, but are not limited to, neurological protection, respiratory stabilization, immune modulation, hematologic and vascular function, and cellular stress and repair pathways. Threat-Targeted Neutralization: Complementing host resilience, efforts focus on developing broad-spectrum medical countermeasures designed to rapidly target, neutralize, and mitigate the effects of CBRN threats. The Government welcomes MCMs and adaptable platform technologies utilized for pre-exposure prophylaxis, post-exposure prophylaxis, or acute treatment. Preferred therapeutic candidates must possess robust environmental stability, eliminating reliance on cold-chain logistics, and be designed for immediate employment in austere, operational environments. This includes formulations featuring simplified routes of administration (such as oral, intranasal, or autoinjector delivery) that can be administered without specialized medical infrastructure. Therapeutic solutions that offer rapid threat clearance, agent inactivation, disruption of lethal injury cascades, or the immediate cessation of cellular damage through highly simplified dosing regimens are highly sought after to preserve combat power and maximize return-to-duty rates. Diagnostic Development: Host-Directed, Agent-Specific, and Pathogen Agnostic Solutions and Diagnostic Decision Support Tools: Efforts focus on developing and maturing agile, far-forward medical diagnostic capabilities. An additional area of interest is diagnostic decision support tools. The Government welcomes innovative, platform-agnostic diagnostic instrument and/or assay prototypes designed for immediate employment in austere, operational environments without reliance on specialized laboratory infrastructure. Preferred diagnostic systems must be optimized for point-of-need use (simple, portable, battery operable or unpowered) and feature simplified sample-collection to enable employment in austere medical environments while being operated by minimally trained users. Specific areas of testing interest include pathogen specific tests, host-response tests to identify infection or physiological dysregulation due to infection, tests that assess antimicrobial resistance or susceptibility, severity of illness, and tests that diagnose toxin exposure in a timeline that supports medical intervention. Of additional interest are test modalities that allow the earliest possible medical intervention relative to the onset of clinical symptoms. 3. Call for Collaborators: Who Should Apply? This announcement serves as an invitation to the full spectrum of MCM developers and support organizations to join the CBRN MCM PBA partner ecosystem. A. MCM Development Collaborators: We invite submissions from developers of MCM candidates relevant to CBRN defense at all stages of advanced development (from Phase I-enabled products through Phase II/III clinical trials and FDA licensure). B. MCM Development Support Collaborators: We also invite participation from organizations specializing in contract research, development, and manufacturing (CROs/CDMOs) and other firms with expertise in preclinical testing (e.g., efficacy, pharmacology, toxicology), clinical trial execution, cGMP manufacturing, regulatory submissions, and advanced modeling. Collaboration with expert service providers is essential to accelerate development. C. Medical Diagnostics Collaborators: We explicitly invite submissions from academic, industry, and non-profit developers of diagnostic platforms, assays, and supporting technologies. This includes developers of: Host-Response Technologies: High-throughput transcriptomic sequencing, host-biomarker assay panels, machine-learning algorithms for physiological anomaly detection, and point-of-care host-response devices. Agent-Specific Technologies: Multiplexed PCR/nucleic acid tests, advanced antigen-detection systems, hand-held or wearable diagnostic sensors, and rapid metagenomic sequencing technologies optimized for austere environments. Enabling Support Partners: Organizations specializing in clinical sample acquisition and biorepository management, analytical/clinical validation of diagnostic devices, biosafety level (BSL-3/4) testing, regulatory FDA clearances for IVDs (In Vitro Diagnostics), and software/data integration for tactical networks. Technology development partners: Organizations willing to sell or share IP with the USG. This IP would be shared with vendors of fielded systems for the purpose of accelerating early assay development and diagnostic target expansion on fielded systems. 4. Submission Requirements & Process Interested entities shall submit a white paper (not to exceed five pages, not including a cover page) that addresses the areas outlined below. In addition, companies shall state entity’s willingness to team or collaborate with other entities within this PBA. A. For MCM Development Collaborators: Your submission should provide a comprehensive overview including: Product Description: A clear description of the product, its mechanism of action, intended use and proposed FDA indication. Efficacy Data: A summary of all significant in vivo and in vitro data and a description of well-controlled and/or good laboratory practices (GLP) data generated in validated animal models against CBRN threats. Regulatory & Clinical Status: A history of U.S. Food and Drug Administration (FDA) sponsor experience and engagements (including IND status), and a summary of completed or ongoing clinical trials (Phase I, II, III), including safety and pharmacokinetic/pharmacodynamic (PK/PD) data. Manufacturing: A description of current manufacturing capacity (scale, good manufacturing practices (GMP) status) and the strategy for scaling production. Company Profile: A summary of your company’s experience in advanced product development, commercialization, and relevant intellectual property rights. B. For MCM Development Support Collaborators: Interested service providers should submit a summary of their core capabilities, relevant experience with complex biologics or small molecules, FDA regulatory experience, available infrastructure, and capacity or technology that can accelerate the development of advanced medical countermeasures. C. For Medical Diagnostics Collaborators: Your submission should provide a comprehensive overview of your diagnostic capabilities, including: Platform & Assay Specifications: A clear description of the diagnostic system (e.g., point-of-need, wearable, laboratory-based, or high-throughput platform), its detection mechanism (agent-specific, host-directed biomarker, or multiplexed), sample input requirements (such as blood, saliva, or non-invasive matrices), and time from patient sample collection to result. Analytical & Clinical Performance: A summary of analytical sensitivity/specificity (limit of detection), dynamic range, and any clinical or mock-clinical performance data (including GLP or non-GLP laboratory evaluation data) using engineered targets, surrogates, or active CBRN agents. System Ruggedization & Logistics: An evaluation of the platform’s suitability for far-forward or austere environments, including environmental stability (storage temperature and shelf-life of reagents without a cold chain), physical footprint, power requirements, and ease of use by non-specialized personnel. Regulatory Pathway & Cybersecurity: Current FDA regulatory status (e.g., Investigational Device Exemption [IDE], Pre-Submission, 510(k), or De Novo status), and a description of data interface capabilities, including compatibility with military tactical networks and cybersecurity compliance protocols (e.g., Risk Management Framework [RMF] standards). D. Awards: Acceptance into the PBA allows for award of project orders under any program supported by this PBA. 5. Administrative Information & Organizational Background Submission of White Papers: Please submit all white papers to: usarmy.detrick.cpe-cbrnd.mbx.cbrn-mcm-pba@army.mil Points of Contact: Please direct all technical and administrative questions to: Hunter Robinson (hunter.t.robinson4.civ@army.mil) Alexander Mayatte (alexander.z.mayatte.civ@army.mil) Issuing Organization Mission: CPE CBRND advances the development of CBRN defense capabilities to enable the Joint Force to fight and win in a CBRN contested environment, contributing toward National Defense Strategy priorities. Authority: Projects may be awarded under the authority of 10 U.S.C §4021, 10 U.S.C. §4022, and 10 U.S.C. §4023. These agreements are not subject to the provisions of the Competition in Contracting Act of 1984. SAM Registration: Prospective awardees MUST be registered in the System for Award Management (SAM) database prior to submitting an invoice and through final payment.
39%
Special NoticeOpen
**28 September 2026: Amendment 02 — Annual Update & Commercial Solutions Opening (CSO) Revisions** Solicitation: FA238424S2336, "Open Period 3 - All Technical Areas, 10 U.S.C. 3458 - Commercial Solutions Opening (CSO)" Solicitation Authority: 10 U.S.C. § 3458 - Authority to acquire innovative commercial products and commercial services using general solicitation competitive procedures (R-DFARS Part 212) The purpose of this update (Amendment 02) is to incorporate annual solicitation updates, align applicable commercial provisions and clauses with current RFO and DoD cybersecurity requirements, and reaffirm submission guidelines for commercial solutions. SUMMARY OF REVISIONS (AMENDMENT 02): 1. Commercial Innovation Scope (10 U.S.C. § 3458): Proposals submitted under this CSO must provide innovative commercial products, commercial technologies, or commercial services that meet or exceed 711 HPW operational requirements. Solutions must demonstrate commercial viability or novel adaptation of commercial technology for military utilization. 2. Provisions and Clauses Update: Attachment 1 has been updated to reflect current RFO commercial contracting provisions and mandatory DoD cybersecurity safeguarding requirements (including NIST SP 800-171 SPRS assessment posting and task-specific CMMC compliance per DFARS 252.204-7019, 7020, and 7021). 3. Contract Types & Terms: Awards resulting from this CSO may include fixed-price commercial contracts, Other Transactions under 10 U.S.C. § 4022, or other authorized commercial acquisition vehicles. 4. Reference to Updated Overarching Industry Guide: Offerors must refer to the revised CHEERS Industry Guide (Revision September 2026) located on the parent MAA notice for detailed submission templates and instructions. List of Attachments: 1. "Open Period Solicitation 3_CSO Amend 02.pdf" 2. "Attachment 1 - List of Provisions and Clauses (CSO).pdf" Related Notice: Multiple Authority Announcement (MAA) FA238424S2233, "Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS)" Note: You MUST refer to the related notice identified above in order to obtain all additional attachments referenced herein (e.g. CHEERS Industry Guide, Statements of Objectives (SOO), and S&T Protection Appendices). Previous Amendment History 20 Nov 2025: Amendment 01 - Annual Update Solicitation: FA238424S2336, "Open Period 3 - All Technical Areas" Solicitation Authority: 10 U.S.C. 3458 - Commercial Solutions Opening (CSO) List of Attachments: 1. "Open Period Solicitation 3_CSO Amend 01" 2. "Attachment 1 - List of Provisions and Clauses_CSO" Related Notice: Multiple Authority Announcement (MAA) FA238424S2233, "Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS)" Note: You MUST refer to the related notice identified above in order to obtain all additional attachments referenced herein (e.g. CHEERS Industry Guide, Statements of Objectives (SOO), and S&T Protection Appendices)
39%
Solicitation09/30/2028

Additional Details

Solicitation Number

68HE0B21Q0175

Archive Date

Oct 8, 2021

Office Address

RESEARCH TRIANGLE PAR, NC, 27709